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 Bacillus subtilis is a rod shaped gram-positive bacterium that has been extensively 
studied for decades.  The scientific interest lies, in large part, to its use as a model 
organism for the study of sporulation, which is a simple form of cell differentiation.  It is 
also a very important organism in industry and everyday life as it is used to produce 
antibiotics, and other important compounds.  B. subtilis is also used as a probiotic and as 
an additive to organic fertilizers and plant treatments because of its antifungal properties. 
 The regulation of the initiation and continuation of sporulation has been well 
studied, but the metabolic changes the cell must go through are still in question and the 
subject of current study.  One of the metabolic changes that happens in the cell is the 
activation of the mmg operon by σE in the mother cell during sporulation.  This operon is 
composed of six genes that encode a putative fatty acid degradation pathway and the 
methylcitric acid cycle.  This cycle takes propionyl-CoA (a fatty acid degradation 
metabolite) and condenses it with oxaloacetate into 2-methylcitrate, and through the rest 
of the cycle produces pyruvate and succinate that can enter the citric acid cycle. 
 One gene in the middle of the putative methylcitric acid cycle is mmgE.  This 
gene has not previously been studied.  Its sequence, both genetic and proteomic, are a 
very close match to 2-methylcitrate dehydratases found in other organisms like 
Escherichia coli and Salmonella typhimurium.   
 The mmgE gene was cloned into an overexpression strain of E. coli and the 
protein was isolated for study through Ni-NTA chromatography.  Through UV/Vis 
spectrometry, high performance liquid chromatography (HPLC), and mass spectrometry 
the activity of this enzyme, on 2-methylcitrate, was studied.  It was found that this 
enzyme does perform 2-methylcitrate dehydratase activity.  
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CHAPTER I 
BACKGROUND 
 
I. A Sporulation 
 
The overall study of Bacillus subtilis mainly focuses on the mechanism of 
sporulation. (1)  This is just one physiological process of the bacterium but it is  complex 
and important to understand. (1)  Just how complex is fairly well understood as more than 
a hundred genes (at least partially), and many other factors that control transcription and 
translation, are involved in this entire process. (1)  Sporulation is an energetically 
intensive process that creates a thermally, and chemically resistant compartment 
containing genetic material and necessary proteins. (2)  This compartment is called a 
spore and can survive everything short of incineration. (2)  The initiator of sporulation is 
a transcription factor encoded by Spo0A. (2)   
 Spo0A is the ultimate initiator of sporulation.  It exists in an inactivated state until 
phosphorylated.  There exists a system called the phosphorelay to transfer a phosphate 
onto Spo0A, activating it.  This involves three histidine kinases which eventually pass the 
phosphate on to Spo0F which then passes it onto Spo0B, and finally to Spo0A.  This 
relay makes for easy regulation at multiple points as each step in the path can be inhibited 
(3). For example a regulatory protein, RapA, inhibits Spo0F through dephosphorylation.  
Since this is an energetically sensitive time for a B. subtilis cell the phosphorelay allows 
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for strong regulation without the energy expense of a kinase cascade.  A kinase 
phosphorylation cascade would require the use of an ATP at each phosphorylation so the 
amount of energy that would go into initiating phosphorylation would be much higher.  
The phosphorelay only requires a single ATP for each run through the whole pathway. 
 Once activated as Spo0A~P this protein acts as a transcription factor that is 
responsible for the appearance of σF (1).  The way that the phosphorylated form of 
Spo0A controls the entry into sporulation is by the ratio of Spo0A~P:Spo0A.  Higher and 
higher concentrations of Spo0A~P cause activation of more and more processes as the 
series of sporulation events is linked to the concentration of the active form of Spo0A (4) 
(3).  The concentration of Spo0A increases once activated due to a positive feedback loop 
that is controlled by Spo0A itself as it acts as its own transcription factor.   
 Under favorable growth conditions the bacterial cell divides in two after doubling 
in size.  This is the normal life cycle of the cell and known as stage zero of sporulation.  
Under any of the aforementioned unfavorable conditions the cells leaves the static stage 
zero and enters stage one.  Stage one is characterized by the chromosomes lining up 
along the long axis of the cell as the septum begins to form at one pole directed by a ring 
of FtsZ, an analog of tubulin, that is a major component of eukaryotic cell division (4).  
FtsZ along with SpoIIE direct the division of the cell to one of the poles.  Without SpoIIE 
activation the cell would divide along the cellular midpoint between the poles, just like a 
stage zero cell (4).   
 Stage II of sporulation starts once the chromosome has lined up from pole to pole 
and the septum forms (4).  This internal peptidoglycan wall segregates the early prespore 
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from the mother cell.  With the way the chromosome lines up in the cell, approximately 
thirty percent of it is in the prespore with the rest having to be transported across by 
SpoIIIE (4).  This DNA translocase forms a pore in the septum and allows the rest of the 
necessary DNA to be transported into the prespore (4).  The next thing to happen after 
division is to have simultaneous gene transcription follow different programs in the 
mother cell and prespore, since these two components are to become vastly different.  
There are two sigma factors that are responsible for the difference in transcription 
between the mother cell and prespore: σE in the mother cell, and σF in the prespore.  The 
prespore σF is regulated by two other factors: SpoIIAB and SpoIIAA.  SpoIIAB is an 
anti-sigma factor as it binds to and inactivates σF.  The SpoIIAB- σF complex exists 
during the normal life cycle of B. subtilis but since they are complexed it is inactive.  
Once the cell has divided into the prespore and mother cell in stage II SpoIIAA is 
transcribed in the prespore (4).  It interacts with the SpoIIAB- σF complex and causes σF 
to be displaced and active.  After σF has been activated in the prespore spoIIR is 
transcribed and moves to the mother cell to activate σE (1).  This sigma factor controls 
transcription of genes in the mother cell (1).  Before activation σE exists in a pre-σE form 
(1) (5).  This inactive form of σE is signaled to begin transcription, pre-division, by 
Spo0A~P, so its production is linked to sporulation initiation and is not present at any 
other time (1) (6).  This sigma factor is a member of the spoIIG operon and Spo0A~P 
also induces transcription of SpoIIGA which is the enzyme that activates σE by cleaving a 
twenty-seven residue amino acid sequence from the N-terminus of the pre-σE (1) (6)  
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After transcription differentiation has occurred the cell moves into the stage III of 
sporulation, which is engulfment.  The mother cell produces proteins that slowly degrade 
the peptidoglycan septum.  This removes the separation between the prespore, which 
remains in its subterminal location, and the mother cell.  This is described as a 
“phagocytic” process (1).  This is due to the fact that the mother cell engulfs the prespore.  
At this point the mother cell also demonstrates some control over the gene transcription 
in the prespore.  The SpoIIIG gene begins to be transcribed an hour after engulfment and 
σE is necessary for this to occur (1).  The signaling mechanism is not known beyond the 
link to σE.  This gene is necessary for the completion of engulfment since it encodes σG ( 
(4).  This sigma factor controls entry into the rest of sporulation (4).  At this point the 
prespore is far from complete as it is lacking the tough outer coatings characteristic of a 
mature spore. 
 Two tough coatings are formed and cover the prespore in the next two stages of 
sporulation.  The interior of the prespore changes drastically as well.  This internal 
change is formed by a multitude of small proteins, produced in the prespore, that cover 
the DNA.  During this process dipicolinic acid, produced in the mother cell, and large 
amounts of metal ions are absorbed by the prespore (4).  This all goes towards hardening 
the prespore to protect the DNA against any harsh (4).  While the prespore is changing 
internally, the cortex, a peptidoglycan cell wall, is formed on the outside.  This is quickly 
followed by the spore coat which is a protein-based covering that forms on the exterior of 
the cortex.  Once these two coverings are formed and the core completed the spore is 
ready and the mother cell lyses. 
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I. B The mmg Operon 
 
There are many genes in the B. subtilis genome that encode for the use of various 
sources of carbon as nutrients for cellular needs (7).  Of these there seems to be a distinct 
need for branched short-chained acids for producing the fatty acids needed for various 
cellular demands such as membrane production (7).  B. subtilis can make and use a wide 
variety of these molecules and this is where the mmg operon becomes important in 
sporulation.  The metabolic processes for the vegetative state and early sporulation are 
known and well-studied, such as glycolysis and the Krebs cycle (5).  Once sporulation 
begins it causes distinct metabolic changes in the cell as it prepares the new spore (5).   
As stated previously gene transcription becomes differentiated between the prespore and 
the mother cell, and this is true for metabolism.  In the later stages of sporulation the 
prespore starts producing glucose dehydrogenase as the mother cell begins glycogen 
production (5).  Intermediate stage metabolism isn’t as well understood and is also when 
the mmg operon becomes active.  
As stated previously σE controls transcription of several genes in the mother cell 
during sporulation (5).  One such set of genes are the “mother cell metabolic genes” that 
are known as the mmg operon.  This operon consists of six genes: mmgA, mmgB, mmgC, 
mmgD, mmgE, and yqiQ (8).  The first five genes in this operon were described by Bryan 
et al in 1996 after systematically screening for σE dependent open reading frames.  
MmgA-E were found through this screening and later on Kunst et al found the sixth 
member of the operon through genome sequencing and gene annotation (7) (5).  This last 
member was named yqiQ (7). 
6 
 
 
 
Figure 1.  The mmg operon. (8) 
 
 
The first three enzymes of the operon, mmgA-C, are part of fatty acid 
degradation.  MmgA was found to encode an acetoacetyl-CoA thiolase by Reddick and 
Williams (8).  Work in the Reddick group also showed that mmgB encodes a 3-
hydroxybutryl-CoA dehydrogenase (5) (9) and mmgC encodes an acyl-CoA 
dehydrogenase (5) (10) (11).  MmgD is the third citrate synthase to be found in B. 
subtilis, and the Reddick group has shown that it has 2-methylcitrate synthase activity 
(12) (5) (11).  The next gene in the operon, mmgE, is similar by sequence to 2-
methylcitrate dehydratase.  YqiQ is likely a 2-methylcitrate lyase (7) (13) (11). 
I. C Methylcitric Acid Cycle  
 
 
Escherichia coli has previously been shown to have a methylcitric acid cycle (14).  
This cycle becomes fully active under glucose deficiency, and in the presence of 
propionate (14).  Short chain fatty acids can be used as a carbon source by having 
propionyl-CoA be converted to citric acid cycle substrates (pyruvate and succinate).  The 
ability for an organism to do this not only allows for continued survival on another 
carbon source, but propionyl-CoA has been shown to be an inhibitor if it is allowed to 
build up within the cell (15)  Having this capability also allows for gluconeogenesis if the 
cell is starved for glucose. (15)   
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 The genes that make it possible for E. coli to metabolize propionate are the 
common methylcitrate enzymes encoded by the prp operon which has the genes 
prpBCDE (16) (17).  These genes encode the ubiquitously required genes for the 
methylcitrate cycle: methylcitrate lyase, methylcitrate synthase, methylcitrate 
dehydratase and propionyl-CoA synthase (16) (17).  The prp genes do not work in this 
order though.  Firstly, propionate needs to be activated by PrpE which attaches coenzyme 
A to propionate forming the active compound, propionyl-CoA, which is now ready to 
enter the main body of the methylcitric acid cycle (16) (18).  The next step is for 
propionyl-CoA to condense with oxaloacetate (a citric acid cycle intermediate) to form 2-
methylcitrate.  This reaction is catalyzed by PrpC, also known as methylcitrate synthase 
(the reaction is shown in Figure 3) (16) (19) (20).  The 2-methylcitrate that is formed by 
PrpC is then acted upon by methylcitrate dehydratase.  This enzyme removes water to 
create, in E. coli, 2-methyl-cis-aconitate (16) (21).  Now at this point another enzyme 
outside of the operon is used to create the substrate for methylisocitrate lyase (16) (21).  
Aconitase, which is a citric acid cycle enzyme, is necessary to add water, into the 
aconitate, to form 2-methylisocitrate (16) (18).  Methylcitrate lyase is the enzyme at the 
very end of the methylcitric acid cycle.  The products (pyruvate and succinate) are 
intermediates of the citric acid cycle and can be used to reform oxaloacetate for another 
round of propionate catabolism (16) (18). 
It was shown by Horswill et al, that Salmonella typhimurium needs the prp operon 
to grow on propionate (19).  The operons in both E. coli and S. typhimurium encode the 
same genes so they were given the same designation for propionate metabolism (16) (19) 
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(17).  The S. typhimurium prp operon does have one more open reading frame: prpR.  
This gene encodes a sigma-54 family transcription activator, which is part of the 
promoter that controls gene activation (22).  This organism has the same basic 
methylcitric acid cycle as E. coli (19) (16).  It has the prpBCDE genes that encode: 
methylisocitrate lyase, methylcitrate synthase, methylcitrase dehydratase, and propionyl-
CoA synthase respectively (19).  These genes perform the same tasks as stated above and 
metabolize propionate into pyruvate and succinate.  Both S. typhimurium and E. coli are 
gram-negative examples of bacteria species that have 2-methylcitric cycles so it is 
something that is common through bacterial species as a whole, especially since 
B.subtilis is a gram-positive species that has a putative methycitrate cycle. 
The entire mmg operon in B. subtilis is likely involved with branched fatty acid 
degradation, as mmgABC are presumably responsible for breakdown of long-chain, and 
branching fatty acids as the indication is that about 85% of B. subtilis fatty acids are 
branched (23) (14).  All three of these genes are involved in odd-iso, even iso, and 
anteiso branched fatty acid degradation (14).  Odd-iso fatty acid metabolism leads 
straight into the citric acid cycle since it produces acetyl-CoA directly, but anteiso and 
even-iso produce propionly-CoA which, with oxaloacetate, is the primary substrate for 
the methylcitrate cycle (14). These fatty acids are good sources of energy and very 
abundant in all of B. subtilis’s natural habitats (23).   Not only can fatty acids be pulled 
from the environment for metabolism but they are present in a multitude of forms in the 
membranes of the B. subtilis cell.  This means that propionate can be funneled into the 
methylcitrate cycle from catabolizing its own lipids.  With how the mmg operon is 
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activated in the mother cell during sporulation it makes sense that it would break down 
cellular lipids to pay the large energy expense likely required for sporulation (5).  
 The breakdown of odd chain fatty acids will lead to propionate production (17).   
This means that mmgABC likely supply of propionate, which goes straight into the main 
part of the methylcitric acid cycle that is encoded by mmgDE and yqiQ (14).  MmgD is a 
gene that transcribes into a protein that is homologous to the prpC genes mentioned 
earlier as it is a citrate synthase, and actually the third one in B. subtilis (6) (16) 
(19).  This was a key factor in hypothesizing that B. subtilis has a methyl citric acid cycle 
since protein structure dictates function, having similar structure gives a great possibility 
of similar capabilities. (14) 
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Figure 2.  The methylcitric acid cycle.  All relevant enzymes, from B. subtilis, are in 
bold. (14) 
 
I. D Introduction to MmgE 
 
 
MmgE is a previously uncharacterized enzyme encoded by one gene of the mmg 
operon of Bacillus subtilis.  The gene is 1416 base pairs long and transcribes to a 471 
amino acid protein that is 52,737.6 Da in mass (11) 
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 Salmonella typhmurium is one of the organisms that has been identified to have a 
methylcitric acid cycle and as such has a 2-methylcitrate dehydratase (19). In this 
organism the operon that encodes this set of genes is the prpBCDE operon.  The cycle 
was characterized by mutations in the respective genes and analysis was done by NMR to 
see what intermediates built up in solution (19).  When prpD was mutated to be non-
functional, 2-methylisocitrate did not appear and concentrations of 2-methylcitrate built 
up showing that this enzyme was likely a 2-methylcitrate dehydratase that catalyzes the 
tautomerization of 2-methylcitrate into 2-methlyisocitrate (19). 
Another organism that has been shown to have a methylcitric acid cycle is E. coli 
(16) (18).  The prpD protein in E. coli was determined to dehydrate 2-methylcitrate into 
2-methyl-cis-aconitate requiring the activity of the citric acid cycle aconitase to complete 
the conversion to 2-methylisocitrate, which the isocitrate lyase can cleave into pyruvate 
and succinate (16).  Brock et al also discovered that the PrpD protein was similar to 
MmgE through sequence analysis. 
Work done with Salmonella enterica showed that the prpD enzyme in that 
organism is in fact 2-methylcitrate dehydratase (21).  The enzyme converted 2-
methylcitrate into 2-methyl-cis-aconitate and could not go any further.  This means that 
in some organisms there is the need for another enzyme to convert the methyl aconitate to 
2-methylisocitrate. (21) 
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Figure 3.  The reaction catalyzed by MmgD to form 2-methylcitrate, the substrate  
for MmgE (24). 
 
 
 
Figure 4. The expected reaction catalyzed by MmgE. 
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I. E ClustalW Alignment 
 
 
 
Figure 5.  ClustalW alignment of prpD from Salmonella typhimurium, E.coli strain 
K-12, and Bacillus subtilis strain 168 (24) (25) (26) (27). 
 
 The ClustalW alignment shown in Figure 15 is an alignment of the amino acid 
sequences of the three organisms listed.  The reason for doing this is to show the 
similarity between the sequences of related proteins.  The program works by taking 
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sequences given and aligning them so that the highest percentage of amino acids match 
between sequences.  ClustalW alignments are not necessarily perfect amino acid matches 
as the software will give a higher score (higher means better match) to similar amino 
acids (i.e. acidic, basic, etc…) as a similar amino acid may also allow for similar 
function.  An * on the alignment means that that residue is exactly conserved between the 
amino acid sequences used in the alignment.  When a very similar residue is conserved 
between the sequences a colon is used and a slightly similar amino acid will have a 
period below the alignment at the residue position.  The score given does not equate to a 
percentage of similarity.  It is a score that is derived from the Gonnet PAM250 matrix, 
which determines how similarity is taken into account and not just exact matches.  Less 
than perfect matches lower the score but still show similarity as they should allow the 
enzyme to have similar function (25) . 
 The S. typhimurium to E. coli alignment had a score of 93.0; S. typhimurium to B. 
subilis had a score of 59.0; E. coli to B. subilis had a score of 61.0 (25).  The higher the 
score the better the match and all of these proteins have high sequence identification with 
each other.  This means that they are all similar in structure which means they likely have 
similar functionality.  As long as active site geometry and composition has been 
conserved they should still work the same.  S. typhimurium has a 2-methylcitrate 
dehydratase that is very highly matched to the homologous enzyme in E. coli, but when 
looking at the ClustalW alignment there may be a “:” or “.” which indicate less than 
perfect matches but those symbols are for all of the sequences in the alignment.  In this 
case, the two sequences in question may have a perfect match but since the third is only 
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similar it shows as a lower level of similarity on the alignment.  For a true sense of the 
level of similarity between different sequences one must look at the score and compare 
them relative to the others.   
 The scores between B. subtilis and both S. typhimurium and E. coli show that 
there is a high level of sequence conservation between the 2-methylcitrate dehydrates of 
these two organisms and MmgE of B.subtilis.  Both scores are very similar, which is to 
be expected since the proteins from S. typhimurium and E. coli are so very similar to each 
other.  Since both S. typhimurium and E. coli are Gram-negative a greater level of 
similarity would be expected since they are more similar to each other than to the Gram-
positive B.subtilis.  The fact that MmgE has such a high degree of similarity to PrpD 
from the other two organisms is compelling evidence for it being a 2-methylcitrate 
synthase.  
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CHAPTER II 
EXPERIMENTAL 
 
II. A Project Overview and Goals 
 
 
Currently there are complete genome sequences for several organisms, and new 
ones being completed frequently.  The genome of B. subtilis has been complete for some 
time now.  This allows for amino acid sequences, and probable protein designations, to 
be assigned, but there is an incomplete understanding of metabolic pathways in this or 
any other organism.  This is a problem because, without a complete understanding of an 
organism as a whole it cannot be effectively used as a model organism. 
A long term goal of the Reddick research group is to characterize the mmg operon 
for a better understanding of Bacillus subtilis.  The overall objective of this thesis is to 
characterize mmgE, which is one of the genes in the mmg operon.  The central hypothesis 
is that mmgE encodes 2-methylcitrate dehydratase, which would play a critical role in a 
probable methylcitrate cycle.  The rationale that underlies the research in this thesis is 
that it will provide knowledge of homologous proteins that have the functionality that is 
being proposed for mmgE.  Many other similar organisms have methylcitrate cycles, 
which gives credence to the hypothesis that B. subtilis may have one as well. 
Characterization of this metabolic pathway allows for new investigations of the 
organism’s metabolism since it will be understood at a more complete level.  This is 
important because B. subtilis is a model bacterium used in multitudes of research.   
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Complete understanding of its own inner workings is necessary to fully this bacterium as 
a model and biotechnologically useful organism.  This comprehension cannot be 
achieved through reading sequence data alone as it can be incorrect as to the function of 
specific genes.  We have cloned the mmgE gene into the BL21 STAR over expression 
strain of E. coli (confirmed by sequencing), as well as purified the His-tagged protein 
through Ni-NTA chromatography.  UV/Vis spectrophotometry as well as HPLC were 
used to demonstrate enzymatic activity, and direct infusion/LC-MS for identification 
purposes.  Progress towards the long-term goal of the Reddick laboratory and the 
accomplishment of this Master’s project’s overall objective will be realized through the 
following two specific objectives: 
 
1.  To produce the B. subtilis mmgE protein.  In this specific objective we utilized an 
overall approach involving cloning of the gene into an over expression strain of E. coli, 
BL21 STAR.  The gene was cloned into a pET-200 vector that gave antibiotic 
selectability (kanamycin), and a N-terminus poly-histidine tag to allow for affinity 
chromatography purification of the protein.  Successful cloning was confirmed through 
DNA sequencing and protein purification was checked through SDS-PAGE, and MALDI 
analysis after trypsin digestion, which confirmed protein identity.  
 
2.  To determine the biochemical function of the mmgE protein in B. subtilis.  The 
working hypothesis that we tested is that mmgE encodes a 2-methylcitrate dehydratase. 
This is an important enzyme in the methyl citrate cycle, which is part of branched fatty 
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acid degradation and propionate metabolism. We tested this hypothesis with in vitro 
activity assays.  These assays used substrate turned over by the previously characterized 
protein mmgD (a citrate/2-methylcitrate synthase), as the 2-methylcitrate substrate for 
mmgE as well as recently commercially available 2-methylcitrate purchased from Sigma 
Aldrich.  Activity assays were performed using a UV/Vis spectrophotometer, as well as 
HPLC, to analyze activity and MS direct infusion to identify HPLC peaks. 
II. B Expected Significance 
 
Right now, the full genome of B. subtilis is known, which is the start of having a 
full understanding of the organism.  Understanding mmgE, and by extension the mmg 
operon, is important to the B. subtilis field.  Characterizing the full operon proves or 
disproves proposed protein designations and shows what metabolic pathways are present 
within the organism.  Knowing these pathways allows for better use of B. subtilis as a 
model organism as well as add to the knowledgebase of metabolic biochemistry and 
bioinformatics.  Better understanding of the biochemistry of one organism can help with 
others since new methods and comparisons can be made.  Gene annotation is important in 
this endeavor, but annotation tools are not infallible and errors have been found 
before.  Experimentally characterizing each gene is necessary to be completely certain of 
identities, functions, and to elucidate metabolic pathways 
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II. C Cloning of mmgE 
 
The mmgE gene was first isolated through PCR using Phusion polymerase and 
genomic DNA isolated from B. subtilis strain 168.  The primers used were: 5’- 
TTACATGCAGAACATGTCTACGAATTCATTTAC-3’, and 5’-
CACCATGCCGAAAACGGATCGTG-3’, with the following thermocycler 
conditions:    30 s at 98 °C; 30 cycles of 98 °C (10 s), 55 °C (30 s), and 72 °C (60 s); after 
the 30 cycles the temperature was held at 72 °C for 10 min.  After the reaction was 
complete the sample was held at 4 °C until the next steps.   
The PCR product was purified from the reaction using the PCR Purification Kit 
from Qiagen, according to the manufacturer’s instructions.  The resulting sample was 
analyzed by 1% agarose gel electrophoresis.  The correctly-sized PCR fragment (mmgE = 
1416 bp) was immediately cloned into pET-200 using  topoisomerase-based cloning, 
using the TOPO-cloning kit from Invitrogen, according to the manufacturer’s 
instructions.  All transformations and propagation of plasmids were done using TOP10 
chemically competent E. coli (also from Invitrogen).   
The PCR design was such that the mmgE gene was cloned in-frame with an N-
terminal His6-Tag encoded by the pET-200 plasmid.  The plasmid was sequenced by dye-
terminated sequencing (SeqWright, Inc.), and the length of the mmgE gene necessitated 
that this was done by two rounds of sequencing, first using universal primers to sequence 
roughly 600 bp of each end of the gene, followed by new primers designed from these 
sequences to yield complete coverage of the middle region of the gene.  These two 
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experiments together confirmed that the mmgE thus cloned into pET-200 matched the 
expected sequence reported in the genome project.   
II. D Overexpression of the MmgE Protein 
 
 The vector, containing mmgE, was purified from 5 mL cultures of the TOP10 
cells using the Plasmid Miniprep Kit from Qiagen, according to the manufacturer’s 
instructions.   This isolated DNA was verified by PCR using the cloning primers, with 
analysis by agarose gel electrophoresis, and used to transform BL21 STAR E. coli using 
the kit from Invitrogen and their instructions.  The transformations were plated on LB-
agar plates containing 30µg/mL kanamycin and those with growth were stored at 
4°C.  Colonies were selected and after being restreaked, they were grown up into 
individual 5mL cultures and the plasmid was purified as before.  Each of these purified 
plasmids was analyzed by PCR and agarose gel to confirm the presence of 
mmgE.  The colony that gave the most intense PCR band was selected and used to make 
subsequent plates and a 10% glycerol cell stock that was stored at -80°C.  Large one liter 
flasks of LB were used to grow up enough bacteria for protein-purification.  The LB (10g 
tryptone, 10g NaCl, 5g yeast extract, 1 liter nanopure water pH 7.5) was infected with 1 
mL of a starter culture after adding kanamycin (30µg/mL final concentration) then grown 
until an OD595 of 0.6 was achieved.  Then, IPTG (1mM final concentration) was added 
to induce the culture and it was allowed to shake overnight at 37°C.  The next day the 
culture was centrifuged at 7,480g for 30 minutes at 4°C.  These pellets were stored at -
80°C, or were lysed immediately (in 20mL of 1x binding buffer) by sonicating for six 
21 
 
minutes in thirty second bursts, while on ice.  This cell slurry was then spun at 16,000g, 
for 30 minutes, at 4°C.   
II. E Purification of MmgE 
 
 A 2 mL Ni-NTA column was equilibrated with the following: 6mL of 1x strip 
buffer (0.5M NaCl, 20mM Tris-HCl Ph 7.9), 6mL of DI H2O, 10mL 1x charge buffer 
(50mM nickel sulfate), then 6mL of 1x binding buffer (0.5M NaCl, 20mM Tris-HCl pH 
7.9, 5mM imidazole).  The column can be stored at 4°C with excess binding buffer.  The 
bacteria pellet was resuspended in 10mL of 1x binding buffer and sonicated for six 
minutes (thirty second bursts), while on ice.   Then, after spinning down (16000g), the 
supernatant was added to the column through a 0.45µm syringe filter.  This solution was 
allowed to flow through the column under gravity to load the protein onto the 
column.  After loading, the column was washed with: 20mL of 1x binding buffer, then 12 
mL of 1x wash buffer (0.5M NaCl, 40mM Tris-HCl pH 7.9, 60mM imidazole), and lastly 
12mL of 1x elute buffer (1M imidazole, 0.25M NaCl, 10mM Tris-HCl pH 7.9).  Once 
elute buffer was added 1mL fractions were taken.  As fractions were collected they were 
tested for protein with a quick qualitative assay.  To 1mL of Bradford reagent was added 
33µL of one of the fraction.  If the Bradford reagent turned blue it was indicative of the 
presence of protein so that fraction was saved.  Fraction collection was stopped once 
there was no more protein coming off the column. Fractions collected were analyzed 
through SDS-PAGE to check for a correct sized protein of 57kDa.  Protein containing 
fractions were dialyzed, on the bench top, in four liters of 27mM Tris buffer at pH 
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7.5.  After dialysis the protein solution was aliquoted into microcentrifuge tubes (with 
10% glycerol) and stored at -80°C for use in assays.  MmgE modification:  A 1M 
imidazole concentration in the elute buffer caused a precipitation problem which was 
solved by decreasing it to 200mM imidazole.  MmgD modification:  Binding, wash, and 
elute buffers all have 10% glycerol, but was compatible with 1M imidazole in the elute 
buffer. 
II. F Agarose Gel Protocol 
 
 
To 30mL of 1x TAE, 300mg of agarose was added and heated by microwave until 
completely melted and the solution was homogeneous.  Then, 10µL of ethidium bromide 
was added to the agarose solution, and it was poured into a casting apparatus.  Once 
cooled and set, the gel was placed in the running tray, and samples were added to the 
wells.  Next, 1x TAE was added to the tray until the gel was completely covered, then the 
cover was attached and the gel was run at 120V and 400mA until the dye front was about 
1cm from the bottom edge.  The gel was then imaged using a gel camera and trans UV 
light. 
Samples were prepared by adding 3µL of 6x loading dye to 15µL of the PCR 
product.  The ladder sample was prepared by mixing 1µL of 2-log ladder to 1µL of 6x 
loading dye, and 4µL of microbiology grade water.  
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II. G SDS-PAGE Protocol 
The resolving gel was made by mixing the following reagents in a 50mL Falcon 
tube in order: DI H20: 3400µL, Bis-Acrylamide/Acrylamide: 4000µL, 1.5M Tris Buffer: 
2500µL, Ammonium Persulfate (APS) at 100mg/900µL DI H2O:  120µL20% SDS: 
50µL, TEMED: 15µL.  Samples were prepared by mixing 25µL of the protein sample 
with 75µL of SDS sample buffer.  These samples were heated for five minutes at 
95°C.  The samples were then centrifuged at 15,700g for two minutes.  Once the gel was 
polymerized it was set in the running tub and the inner chamber was filled to the top with 
1x run buffer.  The outer chamber was filled to the proper (2 or 4 gel) line, then the lid 
was placed and the gel was run at 120V and 80mA until the dye front was about a 
centimeter from the bottom.  The gel was then transfered to a tip box and covered with 
staining solution, from 1 liter stock (100mL glacial acetic acid, 500mL DI H2O, 400mL 
methanol, and 1g Coomassie Brilliant Blue R250).  This was then shaken for half an hour 
before being poured off.  Next, destain (same as stain minus the Coomassie Brilliant Blue 
R250) solution was added and allowed to shake for half an hour and the destain was 
repeated until the bands were clearly visible.  SDS-PAGE gels were imaged in the same 
manner as agarose gels. 
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II. H MmgD Purification and Analysis (28) 
 
 MmgD was isolated and purified using the previously stated Ni-NTA column 
protocol, using previously made cell stocks stored at -80°C (from Rejwi Acherya).  After 
purification, and subsequent confirmation SDS-PAGE, an activity assay was performed 
(as per instructions in the thesis written by Rejwi Acharya) to confirm MmgD was 
isolated and make sure the protein was active.  The assay required: 300µM propionyl-
CoA, 5,5’-dithiobis-(2-nitrobenzoate) or DTNB 0.1mM, 20µL of MmgD (any 
concentration), and 500µM oxaloacetate in 1M Tris buffer (28).  Once the MmgD protein 
was determined to be active the same reaction, minus DTNB, was performed to create the 
substrate for MmgE. 
II. I MmgE Activity Assay With MmgD Product 
 
 
MmgD was allowed to turnover product for one hour then the reaction was 
stopped by heating to 95°C for five minutes.  The reaction tube was then cooled and 
centrifuged for two minutes at 15,700g to remove the denatured protein.  Next, the 
solution was transferred to a cuvette and placed in the spectrophotometer, which was set 
at 240nm (16).  The MmgD reaction solution was used to blank the spectrophotometer, 
and then a 100µL aliquot of MmgE was added to the cuvette.  The reaction was inverted 
a few times to mix then immediately placed in the spectrophotometer and data was 
collected for an hour. 
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II. J MmgE Activity Assay with Commercial 2-Methylcitrate 
 
 
Recently 2-methylcitrate has become commercially available, as a trisodium salt 
of  (2RS,3RS)-2-methylcitrate mixture of diastereomers, and new reactions were 
performed using this purchased substrate.  The 2-methylcitrate was stored at -20°C in 
1mL aliquots at a concentration of 20mM.  Reactions were set up using a 1mL total 
volume.  The substrate was at a 1mM concentration and 100µL of isolated MmgE protein 
(any concentration) was added to the reaction buffer (20mM Tris pH 7.5).  The reaction 
was analyzed for one hour at 240 and 220nm in a UV/Vis spectrophotometer.   
 Timed assays were also performed for HPLC analysis.   The reaction components 
were the same as for the UV/Vis spectrophotometer though the protein amount was 
varied in some reactions to 40µL, and 60µL.  These reactions were allowed to run on the 
bench top in 5mL volumes.  Every fifteen minutes a 1mL sample was taken and 
quenched with 100mM potassium phosphate buffer (monobasic) at pH 2.9.  The samples 
were then centrifuged at 15,700g for five minutes before being carefully transferred to 
HPLC vials and injected. 
 One other assay was done with the commercial 2-methylcitrate.  A 1mL solution 
was prepared using the same concentrations as the UV/Vis assay with commercial 
substrate and allowed to run for an hour with a broad spectrum scan (200nm-400nm) 
taken every ten minutes. 
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II. K HPLC Analysis 
 
 
 The first tries at HPLC used two pumps (one with nanopure H2O with 0.1% TFA, 
and the other with methanol and 0.1% TFA).  A C18 column (Waters 3.9mmx150mm 4 
micron) was attached to the HPLC.   Several 250µM solutions were prepared and sent 
through the HPLC to test for separation.  These samples were run with a mobile phase of 
95% water and 5% methanol with a flow rate of 1mL/min and the detector set at 
212nm.  Both MmgD and MmgE reactions were analyzed by the HPLC as well. 
 A new column (Phenomenex Synergi 4u Hydro-RP 80A 250x4.60mm 4 micron) 
was used for the following analyses.  The samples were run through the column at a flow 
rate of 0.700 ml/min.  The mobile phase consisted of 20mM potassium phosphate buffer, 
pH 2.9 and methanol.  A gradient was used that started out 0% methanol which increased 
up to 15% during ten minutes, and held at that concentration for another forty minutes 
then the concentration of methanol decreased to zero over the next ten minutes.  
II. L Mass Spectrometry 
 
 
 Mass spectrometry was performed using two methods on the same triple quad 
device.  The first was direct infusion.  This was performed by pumping a solution directly 
into the ESI source at a rate of 0.5µL/minute.  The lines and syringe were cleaned with an 
excess of acetonitrile solvent between samples.  Data was collected as 200 scans each 
taken every half second.  This data was then averaged to give relative abundance over the 
whole set of scans. 
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 The second method was LC-MS.  This involved using an UPLC in line with the 
ESI source on the triple quad mass spectrometer.  The method used on the UPLC was a 
fifteen minute run with an organic gradient.  The gradient started out with 100% water 
(with 0.19% formic acid) and at three minutes was 90% water/10% methanol.  This 
gradient reverted back to starting conditions at twelve minutes. 
 The enzymatic reaction that was analyzed by this method was the same as 
analyzed by HPLC. but with ammonium bicarbonate buffer (20mM ammonium 
bicarbonate pH 7.5, MmgE, 1mM 2-methylcitrate).  The reaction was allowed to run for 
an excess of two hours to be sure the reaction had run to completion.  No quenching was 
used.  Control experiments were lacking either MmgE or substrate 
II. M CitB Expression 
 
 
The B. subtilis AWS198 mutant strain expressing His-tagged CitB directly from 
the chromosome, was obtained from the Sonensheim group as a glycerol stock and stored 
at -80°C (29).  This stock was used to streak LB agar plates with 34µg/mL 
chloramphenicol.  These plates were grown overnight at 37°C.  Individual colonies off of 
these plates were selected and used to infect 5mL LB starter cultures with 
chloramphenicol and allowed to grow overnight with the cap loose since B. subtilis is an 
obligate aerobe.  Starter cultures were used to infect 1L Difco Sporulation Media (DSM), 
at pH 7.6, broth and allowed to grow to an OD600 of approximately 1.0 and then spun 
down and stored in the -80°C freezer as with other bacteria pellets (29).  The DSM was 
made by adding 8g of bacto nutrient broth (Difco) to 1L of DI water that contains 10% 
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(w/v) KCl and 1.2%(w/v) MgSO4·7H2O (29).  Just prior to use 1mL of each was added: 
1M Ca(NO3)2, 0.01M MnCl2, and 0.001M FeSO4 (29).  The liter of media was then 
infected with a milliliter of a starter culture and allowed to shake at 37°C until the culture 
reached an OD600 of about 1.0.  At this point that culture was split into two large 
centrifuge bottles, balanced, and then spun at 7,480g for 15 minutes at 4°C to pellet the 
bacteria.  These pellets were then washed twice with cold tris-citrate buffer (8g citric 
acid, 20.1g tris, 500mL water) then stored at -80°C until used (29).              
 
II. N CitB Purification 
 
 
The his-tagged protein (CitB aconitase) was purified through Ni-NTA 
chromatography.  The Ni-NTA column was equilibrated with: 6mL of 1x strip buffer, 
6mL of DI water, 10mL of 1x charge buffer, and 6mL of binding buffer then stored at 
4°C until use.  The pellet was resuspended in 10mL of a special buffer (100mL: 1.5g 
KCl, 0.79g Tris-HCl, 10mL glycerol, 10mL nonidet P-40, 0.007g EDTA, 0.017g PMSF, 
0.007g dithiothreitol) and lysed with eight minutes of sonication (30 second bursts on 
ice).  The slurry from sonication was then centrifuged at 15,700g for twenty minutes.  
The supernatant was then added through a 0.45micron syringe filter to the Ni-NTA 
column and allowed to flow under gravity.  Then 20mL of binding buffer(0.5M NaCl, 
20mM Tris-HCl pH 7.9, 5mM imidazole), 12 mL of wash buffer (0.5M NaCl, 40mM 
Tris-HCl pH 7.9, 60mM imidazole), and 12 mL of elute buffer (1M imidazole, 0.25M 
NaCl, 10mM Tris-HCl pH 7.9) were run through the column.  The elute buffer was 
collected in individual 1mL fractions.  These fractions were tested for protein content by 
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mixing 33µL of the fraction with 1mL of Bradford reagent.  If the Bradford reagent turns 
blue then protein was present in the fraction.  This was a qualitative assay as an amount 
was not determined this way.  Samples of each fraction were kept before dialysis (4L 
25mM Tris-HCl, pH 7.5 left on bench top overnight) and stored in -20°C. 
II. O Concentration of Protein Samples 
 
 
Multiple (5) one liter cultures were done to get enough protein solution (10mL) to 
concentrate with a VivaSpin concentrator.  Once the isolation procedure had been 
performed as before and enough protein solution isolated it was all placed in a VivaSpin 
column (5000 MWCO).  This column was placed in a refrigerated centrifuge and spun at 
3000g until concentrated to 1mL.   
II. P CitB Activity Assay 
 
 
Before the assay was started the protein was first allowed to incubate for an hour  
with an activation buffer (100mM Tris-HCl pH 7.4, 1mM Fe(NH4)2(SO4)2, 50 mM L  
Cysteine pH 7.4) (30).  The reaction contained 90mM Tris-HCl pH 8.0, 20mM DL- 
Isocitric acid trisodium and 50µL of the activated protein fraction (29).  The reaction was 
monitored in an UV/Vis  spectrophotometer at 240nm and blanked with just buffer and  
enzyme (29).  The reaction was started by addition of the substrate (isocitric acid).  The  
reaction was monitored for an hour. 
30 
 
CHAPTER III 
RESULTS AND DISCUSSION 
 
 
III. A Cloning of mmgE 
 
 
After PCR, mmgE was cloned by topo isomerase methodology into an over 
expression vector pET200, which was transformed into E. coli, BL21 STAR from 
Invitrogen.  Transformants from the transformation were tested for the presence of mmgE 
by PCR and one transformation was selected for use.  This was due to there being a 
stronger single band at the correct size (1416 Kb) shown in Figure 6.  This transformant 
was used to make a glycerol stock and used for all subsequent experiments.  For complete 
confirmation, DNA sequencing was performed, which conclusively confirmed that mmgE 
was successfully cloned into the pET200 vector. 
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Figure 6.  Agarose gel confirming the presence of mmgE.  Lane 1 was 2-log ladder and 
lane 2 contained the PCR sample.   
 
III. B Purification of MmgE 
 
 
By cloning mmgE into this vector a His6 tag was added to the N-terminus.  This 
allowed for Ni-NTA affinity chromatography for isolation and purification of the protein 
encoded by mmgE.  The one problem encountered while trying to purify MmgE was that 
the 1M imidazole concentration in the elute buffer caused a salting out effect that resulted 
in all the protein in solution to precipitate.  This was solved by reducing the imidazole 
concentration, in that buffer, to 200mM.  SDS-PAGE was performed to check for a good 
purification and that a protein of the correct mass was eluted. 
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 The protein that eluted from the column was used in all UV/Vis 
spectrophotometry and HPLC work.  Before this was done, an in-gel trypsin digest and 
MALDI-MS confirmed that the purified protein matched the sequence of MmgE from B. 
subtilis.  
 
 
Figure 7.  SDS-PAGE of MmgE 
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III. C MmgD 
 
 
To produce the 2-methylcitrate needed as the substrate for MmgE, MmgD was 
purified from a lab strain previously made and stored at -80°C.  The protein had a similar 
sensitivity to precipitating out of solution as MmgE but this was solved by adding 10% 
glycerol to all buffers when performing nickel affinity chromatography, as previously 
described.  Purification was confirmed using SDS-PAGE (see figure 3).  Using an 
UV/Vis spectrophotometer the activity assay, involving DTNB (5.5’-dithiobis-(2-
nitrobenzoate)), for MmgD was performed which showed that MmgD was highly active.  
MmgD was subsequently used, without the DTNB, to produce 2-methylcitrate, the 
substrate for MmgE. 
 
 
Figure 8.  SDS-PAGE of MmgD 
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Each time it was used to produce substrate for MmgE, MmgD was allowed to turn 
over product for an hour, or more, and the change in absorbance in the activity assay for 
MmgD showed that it was performing a reaction.  UV/Vis spectroscopy did not provide 
definitive answers as to the activity of MmgE.  There was a slight slope but never enough 
to equivocally state that MmgE was catalyzing a reaction.  Control experiments were 
done without enzyme and without substrate.  Neither produced the same slight slope as 
the full reaction.  Later UV/Vis spectroscopy was revisited with commercial 2-
methylcitrate.  Activity was observed by an increase in absorbance at 240nm and it was 
theorized that the CoA-SH that was a product of the MmgD reaction was interfering with 
observing the MmgE reaction.   
III. D HPLC 
 
 
Due to the trouble of getting an answer through using the UV/Vis 
spectrophotometer, HPLC was used to check for enzymatic activity.  The first column 
used had a C18 stationary phase and the problem was that this column does not have the 
properties to separate the polar compounds that were being analyzed.  The stationary 
phase of this column consists of a carpet of eighteen-carbon chains which would interact 
the most with non-polar compounds.  This is problematic for getting retention and 
separation of the acids that are both the substrates and products of the enzymes encoded 
by the mmg operon.  2-methylcitrate is quite polar with the three carboxylic acid groups 
in its structure.  We tried to get around this by adding trifluoro acetic acid to change the 
protonation state of the acid groups, as well as varying amounts of methanol in the 
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mobile phase.  None of these variations in protocol changed retention or separation so 
that column was abandoned. 
III. E Phenomenex Synergi Column 
 
 
 The previously mentioned Synergi column from Phenomenex was put in place of 
the C18 column and the mobile phase was changed to 20mM potassium phosphate buffer, 
pH 2.9, and a low concentration methanol gradient was added to help get compounds to 
elute off of the column since the retention was so strong it was taking over an hour to see 
peaks.  As a test, citrate (Figure 9), aconitate (Figure 11), and isocitric acid (Figure 10) 
were easily separated.  Moreover methylcitrate was retained on the column as well, so it 
was decided to proceed with HPLC.  Running a 1mM sample of 2-methylcitrate (Figure 
12) through the column showed that the addition of the single extra methyl group caused 
the compound to stay on the column several minutes longer.  Because of this citrate and 
methylcitrate would elute off of the column at different times.   
 Isocitrate was the quickest compound to elute off of the column at 4.88 minutes, 
referring to Figure 9.  Citrate eluted at 9.43 minutes and the aconitate came off after that 
at 11.54 minutes.  The 2-methylcitrate eluted off of the column with two peaks at 13.99 
minutes and 11.52 minutes (Figure 12).  This means that if an HPLC chromatogram of a 
full MmgE enzymatic reaction has a peak elute after 2-methylcitrate, it should correspond 
to methyl-cis/trans-aconitate. If a new peak elutes before the 2-methylcitrate, it would 
likely correspond to 2-methylisocitrate. 
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Figure 9. HPLC chromatogram of 1mM citrate (isocratic 100% phosphate buffer). 
 
 
 
Figure 10.  1mM isocitrate in phosphate buffer pH 2.9 (isocratic 100% phosphate 
buffer). 
 
 
 
9.43 min
31.9 mVolts 
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Figure 11.  1mM Trans-aconitate in phosphate buffer pH 2.9 (isocratic 100% 
phosphate buffer). 
 
 
Figure 12.  HPLC chromatogram of 1mM 2-methylcitrate (isocratic 100% phosphate 
buffer). 
 
 
  The use of the potassium phosphate buffer, added to the sample for a final 
concentration of 100mM, and to bring the pH to 2.9, was found to sharpen the peaks as 
they were broad when injecting directly with Tris buffer or acetonitrile.  This made the 
purpose of the phosphate buffer quench twofold: first it was to stop the enzyme reaction 
11.52 min
31.2 
mVolts  
13.99 min 
371 mVolts 
11.54 min 
1.08 V 
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so that assays could be analyzed at different stages of completion, and second it improved 
the peak shapes and resolution. 
 
Figure 13. MmgE enzyme reaction at 15 minutes.  Quenched with 100mM 
potassium phosphate buffer pH 2.9. (15% MeOH gradient in phosphate buffer ). 
  
 
 
Figure 14. MmgE enzyme reaction at 30 minutes.  Quenched with 100mM 
potassium phosphate buffer pH 2.9 (15% MeOH gradient in phosphate buffer ). 
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Figure 15. MmgE enzyme reaction at 45 minutes.  Quenched with 100mM 
potassium phosphate buffer pH 2.9 (15% MeOH gradient in phosphate buffer ). 
 
 
Figure 16. MmgE enzyme reaction at 60 minutes.  Quenched with 100mM 
potassium phosphate buffer pH 2.9 (15% MeOH gradient in phosphate buffer ). 
 
 
 Figures 13-16 show a timed reaction of MmgE and 1mM 2-methylcitrate.  Every 
fifteen minutes a sample was taken and quenched with 100mM phosphate buffer, pH 2.9 
then centrifuged for five minutes at 15,700g and then injected into the HPLC.  The timed 
assay shows that the MmgE protein is active and using 2-methylcitrate as its substrate.  
The 2-methylcitrate peak does not decrease in amplitude, in an inverse relationship with 
the product because the commercially available compound is a racemic mixture of 85% 
purity.  This is important because the enzyme can only use one form of it so 75% of the 
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2-methylcitrate remains unreacted no matter how long active enzyme is present.  The 
enzyme can only work with one of the four diastereomers present in the commercial 2-
methylcitrate.  Every fifteen minutes the product peak, at approximately 17.40 minutes, 
 increases in size (essentially doubling) showing that 2-methylcitrate is being converted 
into product. 
The non-methylated compounds can be used as a template for the methylated 
compounds.  Isocitrate eluted first, before citrate, and both aconitate isomers (cis and 
trans) eluted after citrate.  Taking that into account, it is likely just from the HPLC data 
that the product is 2-methyl-cis/trans-aconitate as the product peak elutes after 2-
methylcitrate.  The isomeric form of the aconitate cannot be derived just from this data 
since there was no appreciable separation of the non-methylated aconitate isomers. 
 In addition to the HPLC data, the reaction was viewed again on the UV/Vis 
spectrophotometer as another way to see the reaction in progress.  This time the 
commercial 2-methylcitrate was used as substrate instead of relying on MmgD to 
synthesize it, so that concentration could be controlled with greater confidence. 
III. F Direct Infusion Mass Spectrometry 
 
 The first mass spectrometry, in this project, done was direct infusion mass 
spectrometry on a triple quad mass spectrometer.  Doing this analysis allowed us to 
quickly see an average of the masses ionized by the ESI source.  Each data set was of 200 
scans that were taken every half second.  The data for 2-methylcitrate, Figure 18, shows 
the various masses that 2-methylcitrate exists in: 229, 251, 273, and 295m/z.  All of these 
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masses are missing in Figure 19, which is the sample lacking 2-methylcitrate confirming 
the identity, of the previously mentioned peaks in Figure 18, as 2-methylcitrate.  Each of 
these masses are 22m/z apart because of a different number of sodium cations associating 
with the negatively charged oxygens on the compound.  This figure shows which masses 
to look for in subsequent reactions to see if the substrate, or product, is present. 
 The full reaction is shown in Figure 20, and one thing to note is that there are 
small peaks corresponding to the masses for 2-methylcitrate as shown in Figure 17.  
Some of the substrate remains in solution, and this is expected, because the compound 
was purchased as a mixture of four diastereomers.  The enzyme can only complex with 
one form of the substrate so the others should remain unreacted.  A possible mass for the 
product is the 189m/z peak visible in Figure 20.  This corresponds for the expected mass 
of methylaconitate.  The difference between 2-methylcitrate and the product is the loss of 
water which is 18m/z  This can be compared to the LC-MS results, specifically Figure 
21where the 206m/z peak is visible.  The difference in mass is likely due to the 
association of an ammonium (18m/z) with the product.  The mass of 2-methylcitrate is 
206 mass units, but that peak is not present in Figure 17.  This is because positive ions are 
associating with negatively charged oxygen.  Since the 206m/z peak is missing in the 
chromatograms, of samples having only 2-methylcitrate, we can see that 2-methylcitrate 
normally complexes with at least one ion, so both 189m/z and 206m/z are likely 
candidates for being methylaconitate.   
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Figure 17.  Direct infusion lacking MmgE.  Sample was in 20mM ammonium 
bicarbonate buffer. 
 
 
 
Figure 18. Direct infusion of 2-methylcitrate.  Sample was in nanopure water 
 
 
 
Figure 19.  Direct infusion lacking 2-methylcitrate. 
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Figure 20.  Direct infusion of the full reaction. 
 
III. G LC-MS 
 
 
 The previously mentioned HPLC experiments elucidated activity, by showing a 
new peak appear in a new location.  A probable identification, of the product compound, 
was made relative to the HPLC chromatograms of 2-methyl-cis/trans-aconitate.  This was 
due to comparing elute order and peak characteristics between the methylated and non-
methylated forms of the compounds.  For identification purposes, LC-MS (UPLC in line 
with a triplequad mass spectrometer) and direct infusion MS (triplequad mass 
spectrometer) were performed. These experiments helped to confirm the identity of 
compounds by giving exact masses of compounds that are in the solutions. 
 Full reactions (MmgE protein, 20mM ammonium bicarbonate buffer pH 7.5, and 
1mM 2-methylcitrate) were allowed to run at a room temperature and for an excess of 
two hours to allow for maximum completion.  This was to ensure the maximum amount 
of product was available for mass spectrometry.  The controls were the same as the full 
reaction with each missing a single component for comparison with the complete 
reaction.  One control was lacking 2-methylcitrate and the other was lacking enzyme.  
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The controls were compared to the full enzyme reaction to allow common masses to be 
eliminated so that the product of the reaction is obvious.   
 
 
Figure 21. Control experiment lacking 2-methylcitrate.  MS spectrum of mass range 
100-500 m/z. 
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Figure 22. Control experiment lacking MmgE.  MS spectrum of peak centered at 2.54 
min. 
 
 
 
Figure 23.  LC-MS analysis of MmgE reaction.  MS spectrum of masses centered on 
peaks at 2.53 and 2.67min 
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 Figure 20 shows a series of masses (229, 251, 273, and 295m/z) that correspond 
to the substrate, 2-methylcitrate.  These are all due to different protonation states and the 
fact that it is a trisodium salt.  Each of those masses are approximately twenty-two m/z 
apart with corresponds to the loss of a proton and the gain of a single sodium atom.  The 
peak at 248m/z was in all LC-MS spectra which likely means it is due to solvent and/or 
contamination and there is a peak right next to it, slightly higher m/z that it is masking.  
This higher mass peak that is being masked would likely correspond to one of the 2-
methylcitrate expected masses.  Figure 22 shows very similar masses to Figure 20, both 
of which contain 2-methylcitrate, the only difference being that the sample in Figure 24 
was not dissolved in ammonium bicarbonate buffer, but in nanopure water.  The slight 
difference in m/z between the two figures is likely due to protonation since the water that 
made up the bulk of the mobile phase, for UPLC, was slightly acidified with formic acid.  
The acidification was necessary for creating positive ions through protonation as analysis 
was performed in positive mode. 
 The full enzymatic reaction, which is shown in Figure 21, a single mass stands 
out.  At 206m/z a high relative abundance peak shows up which corresponds to the mass 
expected for methylaconitate if it has complexed with an ammonium.  The formula mass 
of 2-methylcitrate in its pure form is 206 g/mol, but this mass was not present in any 
analysis done lacking MmgE.  The lack of this peak when 2-methylcitrate is not in the 
presence of enzyme shows that it is not present in this form in solution.  It always 
associates with an ion, and positively charged ammonium likely accounts for the change 
in mass.  This means that MmgE catalyzes one step of the reaction that takes 2-
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methylcitrate to 2-methylisocitrate.  If MmgE had produced methylisocitrate a new mass 
would not be visible since the difference between substrate and product, in that case, is 
the location of a hydroxyl group.  This means that another enzyme would be necessary 
for the second step of the reaction to produce 2-methylisocitrate.  Aconitase, encoded by 
citB, in B. subtilis, is the likely candidate for this activity. 
 
 
Figure 24.  A broad spectrum (200-400nm) scan of the MmgE reaction.  Scans taken 
every ten minutes. 
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 Figure 25.  UV/Vis time-course of the mmgE enzymatic reaction at 240nm. 
 
 
 To complement the time-course experiments done with HPLC  UV/Vis 
spectrometry was used to give another way to visualize the reaction.  The time-course, at 
240nm, in Figure 26 shows good activity over an hour.  Previous experiments using the 
UV/Vis spectrophotometer may have had lower levels of activity due to MmgD only 
generating low levels of 2-methylcitrate.  Also, there may have been interference from 
HS-CoA being released into solution from the condensation of propionyl-CoA and 
oxaloacetate to 2-methylcitrate.  Coenzyme-A absorbs at this wavelength, which could 
interfere.  This assay confirms that the shift in peaks seen on the HPLC was in fact 
enzymatic activity due to the MmgE protein interacting with its substrate, 2-
methylcitrate.  Since the product of MmgE was shown to likely by either the cis or trans 
isomer of methyl-aconitate the results are consistent with the dehydrating role of MmgE.  
This removal of water forms the methyl-aconitate but rehydrating activity would have to 
be present to go one more step to 2-methylisocitrate.    There must be another enzyme 
that performs this rehydrating step.  The aconitase enzyme encoded by citB is a good 
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candidate for this activity as aconitase serves the same role in both E. coli and 
Salmonella. 
III. H CitB 	
 
 
The goal of the citB project was to check for methylcitrate cycle activity of  B. 
subtilis aconitase.  There were many difficulties with this project with the biggest being 
protein isolation and purification.  It was possible to get protein from the nickel affinity 
chromatography but it was always in very low concentration, as it was difficult to get a 
good band on a SDS-PAGE.  Partially because of the low concentration, getting activity 
was not possible.  The attempt to remedy this was to purify protein out of several pellets 
of bacteria and then concentrate them using vivaspin columns, which is shown in Figure 
26.  This did not provide an increase in activity as shown in Figure 31. 
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Figure 26. SDS-PAGE of CitB Protein.  Lane 5 has Protein ladder and lanes 1-4 
have highly concentrated citB protein samples. 
 
 
 The next attempt to increase activity came with using activation buffers, 
described by the Sonenshein group and a Sigma Aldrich protocol (30) (29).  They all had 
reducing conditions and iron in solution;  because the aconitase enzyme has an iron-
sulfur cluster that is oxygen sensitive.  What this means is that simply by exposing the 
protein to the atmosphere (which is done upon lysing) oxygen will interact with the 
cluster disrupting activity.  Reducing the cluster and reconstituting with fresh iron can 
restore activity (29) (30).  This was shown through use of an activation buffer on 
commercial aconitase that had great activity.  This was tried on the purified citB protein 
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with no improvement.  This could have been due to the low concentration problems or 
that the cluster was in some way different causing the activation buffer to be ineffective. 
 
 
Figure 27. Aconitase assay with activated CitB. 
 
 
 
Figure 28. Activity assay of activated CitB and isocitrate.   The initial jump in 
absorbance was from the addition of protein.  
 
 
 
Figure 29. Control experiment without CitB 
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Figure 30.  Activity assay with unactivated CitB. 
 
 
 
Figure 31.  Activity assay of aconitase purchased from Sigma Aldrich. 
 
 
 In figures 28-31 various activity assays of citB are shown.  In figures 27 and 30 
unactivated enzyme was used with isocitrate and monitored at 240nm.  Neither of these 
assays showed any activity as there was no slope to the line.  Figure 28 shows a plot that 
at first glance looks like great activity, especially with the initial nearly vertical jump in 
absorbance.  This initial increase in absorbance was from the addition of CitB to the 
reaction mixture.  Any increase in absorbance beyond that was likely due to the rest of 
the reaction mixture as Figure 30 shows that even without any protein there was a steady 
increase in absorbance, which likely means there was a side reaction in the solution.  This 
would likely be due to the activation buffer that was used in this experiment, and the 
heavily reducing conditions it provides.  It was not possible to find activity with these 
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assays due to great inconsistency with the results.  One trial would look like Figure 29, 
with a steady increase in absorbance, then the next (which was exactly the same) would 
look like Figure 28 with no change in absorbance.  Either that and/or the control 
experiments would show that the increase in absorbance was due to something other than 
enzymatic activity.   Figure 31 shows an activity assay using aconitase purchased from 
Sigma Alrdrich, and the activation buffer from Sigma was used.  Aconitase should 
produce repeatable results like in Figure 31, but it did not. 
III. I Conclusion 
 
  
In the course of this work the mmgE gene was successfully cloned and 
overexressed in E.coli, which was confirmed by dye-terminating sequencing.  The protein 
encoded by the mmgE gene was also successfully isolated and purified using Ni-NTA 
chromatography, which was confirmed by both SDS-PAGE and enzyme activity assays.  
The activity seen shows that this protein is 2-methylcitrate dehydratase.  This was shown 
by the activity in the HPLC which showed that its substrate is in fact 2-methylcitrate and 
that its product is a methyl-aconitate.  LC-MS was utilized to confirm the product’s 
identity as methyl-cis/trans-aconitate.  This means that the enzyme has dehydratase but 
not hydratase activity needed to take the pathway to methylisocitrate. 
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